PDS Biotechnology Corporation — Q2 2019 Form 10-Q
Business context and period. The filing covers the three and six months ended June 30, 2019. PDS is a clinical-stage immuno-oncology company developing therapies based on its Versamune platform; it has no approved products and has generated no product revenue. The March 15, 2019 reverse merger with Private PDS makes comparisons with 2018 less meaningful: Private PDS is the accounting acquirer, so prior-period results reflect its standalone business, not the combined company. Share and per-share figures reflect the 1-for-20 reverse split.
Financial results and liquidity
| Metric | Q2 2019 | Six months 2019 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.89 million | $2.92 million |
| General and administrative expense | $2.38 million | $6.29 million |
| Total operating expenses / operating loss | $4.27 million / $(4.27) million | $9.21 million / $(9.21) million |
| Net income (loss) | $(3.89) million | $2.93 million |
| Net income (loss) per share, diluted | $(0.75) | $0.52 |
| Operating cash flow | Not separately presented for quarter | $(8.23) million |
- The six-month net income was driven by an $11.94 million non-cash bargain purchase gain from the merger; it does not indicate profitable operations. Q2 included a $209,449 bargain purchase gain adjustment.
- Expenses rose substantially year over year: Q2 R&D increased $1.72 million and G&A $1.99 million; six-month R&D increased $2.55 million and G&A $5.36 million. Management attributed the increases mainly to clinical-study and personnel costs, public-company costs, and stock-based compensation.
- Cash and cash equivalents were $21.73 million at June 30, versus $103,695 at December 31, 2018. The six-month cash increase of $21.63 million principally reflected $29.11 million of cash received in the merger, offset by operating cash use. Financing activities provided $750,000.
- Current assets were $22.83 million and current liabilities $4.27 million, implying working capital of approximately $18.57 million. Stockholders’ equity was $20.61 million. No convertible notes remained outstanding; the $30,000 note and accrued interest converted into shares at the merger. Operating lease liabilities totaled $1.27 million.
- Operating margins are not meaningful because the company had no revenue. Cash used in operations was $8.23 million for the first half of 2019, compared with $819,703 in the first half of 2018.
Material changes, outlook, and risks
- Management said June 30 cash, together with proceeds expected through government funding programs, was expected to fund operating needs for at least one year after the filing. The company expects continued losses and negative cash flows, and R&D spending to increase as Versamune candidates advance through clinical development. No quantified earnings or revenue guidance was provided.
- The company plans to pursue equity or debt financing, government funding, and selective partnerships. Additional equity could dilute shareholders; debt could impose repayment and covenant obligations. If financing is unavailable on acceptable terms, development programs could be delayed, reduced, or terminated.
- On July 29, 2019, PDS entered an Aspire Capital agreement providing for potential sales of up to $20 million of stock over 30 months, subject to pricing, registration, and share-count conditions. PDS had issued 100,654 shares as consideration for the agreement but had not yet sold purchase shares; management noted uncertainty about using this financing.
- On July 8, 2019, PDS agreed to terminate its office lease effective August 31, with payment of 50% of the stated $665,802 remaining lease payments in three installments through March 2020. No replacement lease had been entered into by the filing date.
- The merger brought in Edge’s discontinued EG-1962/NEWTON 2 program as a $1.22 million in-process R&D asset. PDS was seeking a partner to continue development; the asset’s valuation remained preliminary and subject to review.
- Risks include clinical-trial failure or delay, regulatory and manufacturing hurdles, dependence on third-party research and trial providers, future capital needs, competition, and potential dilution. Merger-related securities lawsuits were settled and dismissed with prejudice. The filing reports no off-balance-sheet arrangements.
Important facts for investors to verify
- Cash runway assumptions, actual operating burn, and whether government funding materializes.
- Progress, cost, and results of PDS0101 and other Versamune clinical programs, including the expected timing of planned trials.
- Whether the Aspire registration becomes effective and whether PDS can access the facility at acceptable prices without excessive dilution.
- Final merger purchase-price allocation, including the bargain purchase gain and EG-1962 IPR&D valuation.
- Cash and obligations associated with the office lease termination, and the company’s ongoing facilities needs.
- Potential share dilution from options and warrants; the filing reported 1.42 million options and 262,758 warrants outstanding at June 30.